Acura Pharmaceuticals, Inc. is an established company that specializes in drug delivery technologies. With three proprietary platform technologies, the company has positioned itself as a leader in addressing the safe use of medications. Acura Pharmaceuticals is focused on research, development, and commercialization, reflecting a mature stage of growth. The company has already established strategic partnerships for commercialization, indicating a stable position in the market.

Acura Pharmaceuticals has achieved significant milestones in the development and commercialization of their technologies. They have successfully licensed their LIMITX™ Technology to Abuse Deterrent Pharmaceuticals LLC for the development of LTX-03, targeting the prevention of opioid overdose. Additionally, their AVERSION® Technology is licensed for OXAYDO® Tablets, the first approved oxycodone product with abuse deterrent labeling in the U.S. Moreover, the IMPEDE® Technology is utilized in Nexafed® products, demonstrating the company's ability to address different areas of medication safety and abuse prevention.

Acura Pharmaceuticals' case studies showcase the real-world impact of their technologies in combating medication abuse and enhancing drug safety. The development of LTX-03 with LIMITX™ Technology illustrates how the company is addressing the critical issue of opioid overdose through innovative drug delivery solutions. The successful commercialization of OXAYDO® Tablets and Nexafed® products further demonstrates Acura's commitment to providing effective abuse deterrent products that benefit both patients and healthcare providers.

Key events in Acura Pharmaceuticals' history include the licensing of their proprietary technologies to established pharmaceutical companies, the FDA approval of OXAYDO® Tablets, and the commercialization of Nexafed® products in the U.S. and Canada. These events highlight the company's strategic collaborations, regulatory achievements, and market expansion efforts, positioning Acura Pharmaceuticals as a key player in the abuse deterrent products market. Additionally, the ongoing research and development activities, along with the focus on product commercialization, underscore the company's commitment to driving innovation and ensuring medication safety.